Replies to post #170970 on Biotech Values

[biomaven0]

>>Ponatinib Dose Modification

That might reassure the FDA some. Interesting that higher platelet counts were a significant risk factor in their model (but unclear if these were actually high in an absolute sense, or just relatively high vs. low counts in other patients).

Also interesting that the MD Andersen front line trial shows not a hint of cardiovascular issues except for some hypertension in a small number of patients.

Peter

[DewDiligence]

Re: ARIA’s ASH poster

From the summary section:

• All pts with dose reduction for >=6 months after achieving MCyR maintained MCyR;
maintenance of CCyR (=94%) and MMR (=75%) was also high [for patients who remained on a constant lowered dose for 6 months after a given kind of response]

In the poster, the second table in the third column shows higher blended percentages for maintenance of CCyR and MMR (by combining the 45mg starting dose and the 30mg starting dose) than the 94% and 75% numbers mentioned above. I presume the discrepancy between these two sets of numbers is that the numbers in the poster table refer to CP-CML patients while the numbers in the summary narrative refer to all patents. However, this isn’t clear, so I might be missing something.